Stockscreener 앱 받기
0.21
2.99%
0.0061
시장 영업 전:
.20
-0.010
-4.76%
전일 마감가:
$0.2039
열려 있는:
$0.2016
하루 거래량:
321.78K
Relative Volume:
0.03
시가총액:
$3.40M
수익:
$7,500
순이익/손실:
$-10.96M
주가수익비율:
-0.0915
EPS:
-2.2943
순현금흐름:
$-11.41M
1주 성능:
+10.53%
1개월 성능:
-4.55%
6개월 성능:
-41.16%
1년 성능:
-26.80%
1일 변동 폭
$0.1966
$0.21
1주일 범위
$0.1847
$0.2181
52주 변동 폭
$0.10
$1.40
Azitra Inc Stock (AZTR) Company Profile
명칭
Azitra Inc
전화
203 646 6446
주소
21 Business Park Drive, Branford
Compare AZTR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.21 | 3.30M | 7,500 | -10.96M | -11.41M | -2.2943 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Azitra Inc 주식(AZTR)의 최신 뉴스
Azitra Inc Financial Disclosures & SEC Filings - TradingView
Azitra Inc (AZTR) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue StageProfit Recovery Report - Newser
AZTR Q1 2026 Earnings: Significant EPS Miss and Stock Decline Amid Pre-Revenue StageEarnings Season Outlook - Newser
AZTR Q1 2026 Earnings: Significant EPS Miss Amidst Early-Stage DevelopmentShort-Term Outlook - Newser
AZTR Q1 2026 Earnings: Massive EPS Miss Exceeds Expectations as Stock Declines Nearly 4%Trade Idea Marketplace - Newser
Azitra (NYSE: AZTR) S-1 shows massive resale dilution and risks - Stock Titan
Azitra (AZTR) Stock: Down -1.58%, Support Test at $0.18 2026-05-19Free Stock Community - Newser
AZTR SEC FilingsAzitra Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Azitra (AZTR) Stock Analysis: Falls -2.40%, Watching $0.20 2026-05-14Profit Surge - newser.com
Azitra 1Q Loss/Shr 25c >AZTR - Moomoo
Branford biotech Azitra expands into consumer skin-care market - Hartford Business Journal
Azitra, Inc. Q1 2024 Financial Report: Operating Expenses, Net Loss, and Key Disclosures - Minichart
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates - PR Newswire
Azitra, Inc. Announces Q1 2026 Financial Results and Pipeline Milestones for Biotherapeutics and Cosmeceuticals - Minichart
Azitra (NYSE: AZTR) widens Q1 loss but lifts cash and equity via new financings - Stock Titan
Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials - TradingView
Azitra, Inc. 1Q 2026: Net loss $(3.93M), EPS $(0.25) — 10-Q Summary - TradingView
Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biotech testing new rash and wrinkle treatments posts Q1 loss, $10.1M cash - Stock Titan
Azitra (NYSE: AZTR) widens Q1 2026 loss but strengthens cash and pipeline - Stock Titan
MSN Money - MSN
Number of shareholders of Azitra Inc – AMEX:AZTR - TradingView
Azitra (NYSE American: AZTR) seeks OK for big share increase and reverse split - Stock Titan
[ARS] Azitra, Inc. SEC Filing - Stock Titan
Azitra granted new U.S. patent protecting ATR-12 program - TipRanks
Azitra receives U.S. patent for Netherton syndrome treatment - Investing.com UK
Azitra receives U.S. patent for Netherton syndrome treatment By Investing.com - Investing.com Australia
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program - PR Newswire
Azitra Inc (AZTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):